How Many Cara Therapeutics, Inc. (NASDAQ:CARA)’s Analysts Are Bullish?

July 11, 2018 - By Clifton Ray

Cara Therapeutics, Inc. (NASDAQ:CARA) LogoInvestors sentiment decreased to 0.83 in Q1 2018. Its down 0.10, from 0.93 in 2017Q4. It worsened, as 13 investors sold Cara Therapeutics, Inc. shares while 27 reduced holdings. 15 funds opened positions while 18 raised stakes. 15.62 million shares or 1.17% less from 15.80 million shares in 2017Q4 were reported.
Great West Life Assurance Can reported 0% in Cara Therapeutics, Inc. (NASDAQ:CARA). Hightower Limited Liability Corp accumulated 17,177 shares or 0% of the stock. Blackrock Inc invested 0% of its portfolio in Cara Therapeutics, Inc. (NASDAQ:CARA). Winslow Evans And Crocker owns 6,280 shares. Us Bank & Trust De has invested 0% of its portfolio in Cara Therapeutics, Inc. (NASDAQ:CARA). Royal Financial Bank Of Canada has invested 0% of its portfolio in Cara Therapeutics, Inc. (NASDAQ:CARA). Moreover, Price T Rowe Assoc Md has 0% invested in Cara Therapeutics, Inc. (NASDAQ:CARA) for 479,275 shares. Tiaa Cref reported 63,799 shares. Rothschild Investment Il owns 22,300 shares. Bancorp Of Ny Mellon has 128,525 shares for 0% of their portfolio. Dekabank Deutsche Girozentrale invested in 0% or 13,500 shares. Shanda Asset Mgmt Holding invested in 54,984 shares. Horrell Management reported 400 shares. Proshare Ltd Com, a Maryland-based fund reported 18,491 shares. Ny State Common Retirement Fund reported 30,100 shares stake.

Since January 24, 2018, it had 0 buys, and 7 sales for $778,740 activity. Shares for $81,000 were sold by CHALMERS DEREK T.

Cara Therapeutics, Inc. (NASDAQ:CARA) Ratings Coverage

Among 5 analysts covering Cara Therapeutics (NASDAQ:CARA), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cara Therapeutics had 9 analyst reports since January 19, 2018 according to SRatingsIntel. The rating was maintained by H.C. Wainwright on Friday, May 11 with “Buy”. The stock of Cara Therapeutics, Inc. (NASDAQ:CARA) has “Buy” rating given on Monday, March 19 by H.C. Wainwright. The rating was upgraded by Janney Capital to “Buy” on Monday, February 12. The stock of Cara Therapeutics, Inc. (NASDAQ:CARA) has “Buy” rating given on Wednesday, May 23 by H.C. Wainwright. On Thursday, March 15 the stock rating was maintained by Canaccord Genuity with “Buy”. The stock of Cara Therapeutics, Inc. (NASDAQ:CARA) has “Buy” rating given on Friday, June 29 by Canaccord Genuity. The rating was maintained by Laidlaw on Thursday, May 24 with “Buy”. H.C. Wainwright reinitiated Cara Therapeutics, Inc. (NASDAQ:CARA) rating on Monday, March 12. H.C. Wainwright has “Buy” rating and $22 target. Below is a list of Cara Therapeutics, Inc. (NASDAQ:CARA) latest ratings and price target changes.

29/06/2018 Broker: Canaccord Genuity Old Rating: Buy New Rating: Buy Old Target: $21 New Target: $22 Maintain
24/05/2018 Broker: Laidlaw Rating: Buy New Target: $26.0000 Maintain
23/05/2018 Broker: H.C. Wainwright Rating: Buy New Target: $24.0000 Maintain
11/05/2018 Broker: H.C. Wainwright Rating: Buy New Target: $22.0000 Maintain
19/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $22.0 Maintain
15/03/2018 Broker: Canaccord Genuity Rating: Buy New Target: $22.0 Maintain
12/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $22 Reinitiate
12/02/2018 Broker: Janney Capital Old Rating: Neutral New Rating: Buy Old Target: $21 Upgrade
19/01/2018 Broker: Seaport Global Rating: Buy New Target: $27 Initiates Coverage On

The stock increased 4.25% or $0.88 during the last trading session, reaching $21.6. About 812,636 shares traded. Cara Therapeutics, Inc. (NASDAQ:CARA) has risen 1.86% since July 11, 2017 and is uptrending. It has underperformed by 10.71% the S&P500.

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors in the United States. The company has market cap of $706.32 million. It is developing product candidates that target the body's peripheral nervous system. It currently has negative earnings. The companyÂ’s lead product candidate comprises I.V.

More notable recent Cara Therapeutics, Inc. (NASDAQ:CARA) news were published by: Nasdaq.com which released: “Here’s Why Cara Therapeutics Jumped 26.3% in May” on June 14, 2018, also Nasdaq.com with their article: “Is Cara Therapeutics, Inc. a Buy?” published on July 01, 2018, Prnewswire.com published: “Canadian Cannabis Market is Projected to Rival California’s” on July 11, 2018. More interesting news about Cara Therapeutics, Inc. (NASDAQ:CARA) were released by: Fool.com and their article: “The Best Marijuana Stocks in the Second Quarter” published on July 04, 2018 as well as Nasdaq.com‘s news article titled: “Cara Therapeutics Announces Dosing of Patients in Phase 2 Trial of Oral KORSUVAâ„¢ (CR845/difelikefalin) for …” with publication date: July 11, 2018.

Cara Therapeutics, Inc. (NASDAQ:CARA) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>